Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979134 · ClinicalTrials.gov registry record · Phase 1
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT00979134 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 95 participants.
The verdict
NCT00979134, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.
Interventions
- DRUG AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2009-10-21 |
| Est. Completion | 2015-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979134
The ClinicalTrials.gov registry entry for NCT00979134 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD4547 is the first listed.
NCT00979134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00979134 about?
NCT00979134 is a clinical study titled "Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours". This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.
What is the current status of trial NCT00979134?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2009-10-21. Estimated completion is 2015-03-05.
What interventions are being tested in trial NCT00979134?
The interventions under investigation include: AZD4547 (DRUG).
Who is sponsoring clinical trial NCT00979134?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.